Helixmith releases topline data on phase 2a trial of Lou Gehrig’s disease drug
05 Sep 2022 //
KOREABIOMED
Helixmith Announces 50% Enrollment in its Clinical Trial for COVID-19
01 Dec 2021 //
PRNEWSWIRE
Helixmith Announces First Patient Enrolled in Ph3 Study of Engensis (VM202)
18 Nov 2020 //
PRWEB